These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22194440)

  • 61. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
    Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.
    Abramson JS; Chen W; Juszczynski P; Takahashi H; Neuberg D; Kutok JL; Takeyama K; Shipp MA
    Br J Haematol; 2009 Feb; 144(3):358-66. PubMed ID: 19036086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC.
    Misso G; Giuberti G; Lombardi A; Grimaldi A; Ricciardiello F; Giordano A; Tagliaferri P; Abbruzzese A; Caraglia M
    J Cell Physiol; 2013 Jan; 228(1):130-41. PubMed ID: 22566192
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
    Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
    Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heat-shock protein 90 inhibitors synergistically enhance melanoma differentiation-associated gene-7-mediated cell killing of human pancreatic carcinoma.
    Zhang Z; Kawamura K; Jiang Y; Shingyoji M; Ma G; Li Q; Hu J; Qi Y; Liu H; Zhang F; Kang S; Shan B; Wang S; Chada S; Tagawa M
    Cancer Gene Ther; 2013 Dec; 20(12):663-70. PubMed ID: 24263157
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Halfdanarson TR; Muders MH; Ames MM
    Pancreas; 2013 Apr; 42(3):411-21. PubMed ID: 23211371
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development and Preclinical Evaluation of
    Wang X; Han Z; Zhang J; Chen M; Meng W
    Mol Pharm; 2024 Oct; 21(10):5238-5246. PubMed ID: 39316366
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma.
    Breinig M; Caldas-Lopes E; Goeppert B; Malz M; Rieker R; Bergmann F; Schirmacher P; Mayer M; Chiosis G; Kern MA
    Hepatology; 2009 Jul; 50(1):102-12. PubMed ID: 19441108
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
    Huyan T; Li Q; Dong DD; Yang H; Zhang J; Huang QS; Yin DC; Shang P
    Immunopharmacol Immunotoxicol; 2016; 38(2):77-86. PubMed ID: 26642940
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.
    Millson SH; Prodromou C; Piper PW
    Biochem Pharmacol; 2010 Jun; 79(11):1581-8. PubMed ID: 20138026
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion.
    Taiyab A; Rao ChM
    Biochim Biophys Acta; 2011 Jan; 1813(1):213-21. PubMed ID: 20883729
    [TBL] [Abstract][Full Text] [Related]  

  • 72. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.
    Wang Y; McAlpine SR
    Chem Commun (Camb); 2015 Jan; 51(8):1410-3. PubMed ID: 25333923
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.
    Georgieva I; Koychev D; Wang Y; Holstein J; Hopfenmüller W; Zeitz M; Grabowski P
    Neuroendocrinology; 2010; 91(2):121-30. PubMed ID: 19923785
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines.
    Senju M; Sueoka N; Sato A; Iwanaga K; Sakao Y; Tomimitsu S; Tominaga M; Irie K; Hayashi S; Sueoka E
    J Cancer Res Clin Oncol; 2006 Mar; 132(3):150-8. PubMed ID: 16283383
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy.
    Tsou YL; Lin YW; Chang HW; Lin HY; Shao HY; Yu SL; Liu CC; Chitra E; Sia C; Chow YH
    PLoS One; 2013; 8(10):e77133. PubMed ID: 24098578
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.
    Giessrigl B; Krieger S; Rosner M; Huttary N; Saiko P; Alami M; Messaoudi S; Peyrat JF; Maciuk A; Gollinger M; Kopf S; Kazlauskas E; Mazal P; Szekeres T; Hengstschläger M; Matulis D; Jäger W; Krupitza G
    Hum Mol Genet; 2012 Nov; 21(21):4615-27. PubMed ID: 22843495
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
    Song D; Chaerkady R; Tan AC; García-García E; Nalli A; Suárez-Gauthier A; López-Ríos F; Zhang XF; Solomon A; Tong J; Read M; Fritz C; Jimeno A; Pandey A; Hidalgo M
    Mol Cancer Ther; 2008 Oct; 7(10):3275-84. PubMed ID: 18852131
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HSP90 affects the stability of BMAL1 and circadian gene expression.
    Schneider R; Linka RM; Reinke H
    J Biol Rhythms; 2014 Apr; 29(2):87-96. PubMed ID: 24682203
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
    Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma.
    Yan W; Xiao J; Liu T; Huang W; Yang X; Wu Z; Huang Q; Qian M
    Tumour Biol; 2013 Jun; 34(3):1391-7. PubMed ID: 23456764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.